$LFVN
Lifevantage Corp Stock $lfvn

$lfvn Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000084914618000041 Filed on February 07, 2018

Income Statement

Concept	2017 Q4	2016 Q4
Revenue	$49.48M	$48.95M
YoY Change	1.09%	-5.86%
Cost Of Revenue	$9.117M	$7.500M
YoY Change	21.56%	-4.36%
Gross Profit	$40.37M	$41.45M
YoY Change	-2.61%	-6.13%
Gross Profit Margin	81.58%	84.68%
Selling, General & Admin	$14.64M	$17.21M
YoY Change	-14.9%	24.47%
% of Gross Profit	36.28%	41.52%
Research & Development	$300.0K	$300.0K
YoY Change	0.0%
% of Gross Profit	0.74%	0.72%
Depreciation & Amortization	$320.0K	$420.0K
YoY Change	-23.81%	-6.67%
% of Gross Profit	0.79%	1.01%
Operating Expenses	$38.04M	$40.75M
YoY Change	-6.65%	-0.91%
Operating Profit	$2.327M	$700.0K
YoY Change	232.43%	-76.91%
Interest Expense	$103.0K	$138.0K
YoY Change	-25.36%	-77.71%
% of Operating Profit	4.43%	19.71%
Other Income/Expense, Net	-$272.0K	-$288.0K
YoY Change	-5.56%	-53.02%
Pretax Income	$2.055M	$412.0K
YoY Change	398.79%	-82.97%
Income Tax	$1.738M	$129.0K
% Of Pretax Income	84.57%	31.31%
Net Earnings	$317.0K	$283.0K
YoY Change	12.01%	-82.31%
Net Earnings / Revenue	0.64%	0.58%
Basic Earnings Per Share	$0.02	$0.02
Diluted Earnings Per Share	$0.02	$0.02
COMMON SHARES
Basic Shares Outstanding	13.96M shares	13.84M shares
Diluted Shares Outstanding	14.15M shares	14.13M shares

Balance Sheet

Concept	2017 Q4	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.79M	$11.73M
YoY Change	9.04%	-25.85%
Cash & Equivalents	$12.79M	$9.202M
Short-Term Investments
Other Short-Term Assets	$4.050M	$1.990M
YoY Change	103.52%	-67.43%
Inventory	$16.82M	$21.38M
Prepaid Expenses
Receivables	$1.542M	$717.0K
Other Receivables	$90.00K	$900.0K
Total Short-Term Assets	$35.29M	$36.72M
YoY Change	-3.89%	0.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.644M	$2.885M
YoY Change	60.97%	-44.31%
Goodwill
YoY Change
Intangibles	$1.181M	$1.698M
YoY Change	-30.45%	-6.29%
Long-Term Investments
YoY Change
Other Assets	$1.142M	$1.305M
YoY Change	-12.49%	6.7%
Total Long-Term Assets	$10.36M	$9.794M
YoY Change	5.81%	15.99%
TOTAL ASSETS
Total Short-Term Assets	$35.29M	$36.72M
Total Long-Term Assets	$10.36M	$9.794M
Total Assets	$45.66M	$46.52M
YoY Change	-1.85%	3.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.269M	$5.037M
YoY Change	-35.1%	-14.0%
Accrued Expenses	$17.05M	$16.50M
YoY Change	3.33%	-1.43%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.000M	$2.000M
YoY Change	0.0%	-83.65%
Total Short-Term Liabilities	$22.73M	$23.54M
YoY Change	-3.45%	-32.41%
LONG-TERM LIABILITIES
Long-Term Debt	$4.457M	$6.424M
YoY Change	-30.62%	518.29%
Other Long-Term Liabilities	$1.966M	$2.041M
YoY Change	-3.67%	-0.68%
Total Long-Term Liabilities	$6.423M	$8.465M
YoY Change	-24.12%	173.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.73M	$23.54M
Total Long-Term Liabilities	$6.423M	$8.465M
Total Liabilities	$29.15M	$32.00M
YoY Change	-8.91%	-15.6%
SHAREHOLDERS EQUITY
Retained Earnings	-$106.1M	-$106.6M
YoY Change	-0.47%	-4.32%
Common Stock	$122.6M	$121.2M
YoY Change	1.21%	2.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$16.51M	$14.51M
YoY Change
Total Liabilities & Shareholders Equity	$45.66M	$46.52M
YoY Change	-1.85%	3.53%

Cashflow Statement

Concept	2017 Q4	2016 Q4
OPERATING ACTIVITIES
Net Income	$317.0K	$283.0K
YoY Change	12.01%	-82.31%
Depreciation, Depletion And Amortization	$320.0K	$420.0K
YoY Change	-23.81%	-6.67%
Cash From Operating Activities	$2.180M	$2.220M
YoY Change	-1.8%	-60.85%
INVESTING ACTIVITIES
Capital Expenditures	-$940.0K	-$150.0K
YoY Change	526.67%	-54.55%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$940.0K	-$150.0K
YoY Change	526.67%	-54.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-750.0K	-490.0K
YoY Change	53.06%	-84.59%
NET CHANGE
Cash From Operating Activities	2.180M	2.220M
Cash From Investing Activities	-940.0K	-150.0K
Cash From Financing Activities	-750.0K	-490.0K
Net Change In Cash	490.0K	1.580M
YoY Change	-68.99%	-26.85%
FREE CASH FLOW
Cash From Operating Activities	$2.180M	$2.220M
Capital Expenditures	-$940.0K	-$150.0K
Free Cash Flow	$3.120M	$2.370M
YoY Change	31.65%	-60.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	43000	shares
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-100000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1028000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	9000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	6000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000849146
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14209628	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Lifevantage Corp
	dei	Trading Symbol TradingSymbol	LFVN
CY2016Q4	lfvn	Commission And Incentives CommissionAndIncentives	23540000	USD
	lfvn	Commission And Incentives CommissionAndIncentives	49836000	USD
CY2017Q4	lfvn	Commission And Incentives CommissionAndIncentives	23395000	USD
	lfvn	Commission And Incentives CommissionAndIncentives	46804000	USD
	lfvn	Money Back Guarantee Period MoneyBackGuaranteePeriod	P30D
	lfvn	Number Of Geographic Segments NumberOfGeographicSegments	2	Segment
CY2017Q4	lfvn	Percent Of Restocking Fee PercentOfRestockingFee	0.1
CY2017Q2	lfvn	Reserve For Sales Returns ReserveForSalesReturns	400000	USD
CY2017Q4	lfvn	Reserve For Sales Returns ReserveForSalesReturns	300000	USD
CY2017Q4	lfvn	Revenue Recognition Sale Returns Acceptable Percentage From Terminated Distributors RevenueRecognitionSaleReturnsAcceptablePercentageFromTerminatedDistributors	0.3
CY2016Q4	lfvn	Sharebased Compensation Arrangementby Sharebased Payment Award Increase Decreaseof Sharebased Liabilities SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseDecreaseofSharebasedLiabilities	100000	USD
	lfvn	Sharebased Compensation Arrangementby Sharebased Payment Award Increase Decreaseof Sharebased Liabilities SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseDecreaseofSharebasedLiabilities	200000	USD
CY2017Q4	lfvn	Sharebased Compensation Arrangementby Sharebased Payment Award Increase Decreaseof Sharebased Liabilities SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseDecreaseofSharebasedLiabilities	200000	USD
	lfvn	Sharebased Compensation Arrangementby Sharebased Payment Award Increase Decreaseof Sharebased Liabilities SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseDecreaseofSharebasedLiabilities	400000	USD
	lfvn	Tax Cuts And Jobs Actof2017 Change In Tax Rate Deferred Tax Asset Income Tax Expense Benefit TaxCutsAndJobsActof2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit	1200000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4850000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3269000	USD
CY2017Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1334000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1542000	USD
CY2017Q2	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	6837000	USD
CY2017Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	6692000	USD
CY2017Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-94000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-28000	USD
CY2017Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	121599000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	122627000	USD
CY2016Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	300000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1000000	USD
CY2017Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	600000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	10000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1000000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	6000	USD
CY2016Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	100000	shares
CY2017Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	100000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	300000	shares
CY2017Q2	us-gaap	Assets Assets	45249000	USD
CY2017Q4	us-gaap	Assets Assets	45656000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	35546000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	35293000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7883000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11731000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11458000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12794000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3848000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1336000	USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14232000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14211000	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14232000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14211000	shares
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	14000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	14000	USD
CY2016Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	94000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1365000	USD
CY2017Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	363000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1200000	USD
CY2016Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7500000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	16332000	USD
CY2017Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9117000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	17856000	USD
CY2017Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	5500000	USD
CY2017Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	4500000	USD
CY2017Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	60000	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	43000	USD
CY2017Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	6500000	USD
CY2017Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	4087000	USD
CY2017Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	3396000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	690000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	826000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	672000	USD
CY2017Q4	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-100000	USD
CY2016Q4	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	200000	USD
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	100000	USD
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-22000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	21000	USD
CY2017Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.351
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.658
	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.352
CY2016Q4	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-300000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-400000	USD
CY2017Q4	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-100000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-8000	USD
CY2016Q4	us-gaap	Gross Profit GrossProfit	41447000	USD
	us-gaap	Gross Profit GrossProfit	87509000	USD
CY2017Q4	us-gaap	Gross Profit GrossProfit	40365000	USD
	us-gaap	Gross Profit GrossProfit	80753000	USD
CY2016Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	412000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2090000	USD
CY2017Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2055000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	3313000	USD
CY2016Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	129000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	627000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	600000	USD
CY2017Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1738000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2179000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2200000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1682000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	471000	USD
CY2017Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	913000	USD
CY2017Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	86000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3791000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1582000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-455000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	218000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1206000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	192000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1341000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	817000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	903000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-410000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-827000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3366000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	215000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-72000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-104000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1115000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-3062000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1202000	USD
CY2016Q4	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	42000	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	44000	shares
CY2017Q4	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2016Q4	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	250000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	302000	shares
CY2017Q4	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	197000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	158000	shares
	us-gaap	Operating Income Loss OperatingIncomeLoss	2686000	USD
CY2017Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1247000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1181000	USD
CY2016Q4	us-gaap	Interest Expense InterestExpense	138000	USD
	us-gaap	Interest Expense InterestExpense	275000	USD
CY2017Q4	us-gaap	Interest Expense InterestExpense	103000	USD
	us-gaap	Interest Expense InterestExpense	265000	USD
	us-gaap	Interest Paid InterestPaid	233000	USD
	us-gaap	Interest Paid InterestPaid	183000	USD
CY2017Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7817000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	9136000	USD
CY2017Q2	us-gaap	Inventory Net InventoryNet	16575000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	16819000	USD
CY2017Q2	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	8758000	USD
CY2017Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	7683000	USD
CY2017Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	900000	USD
CY2017Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1400000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	30722000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	29151000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	45249000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	45656000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	23355000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22728000	USD
CY2017Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2000000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2000000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	5500000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	1000000	USD
CY2017Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5440000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4457000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-993000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1250000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-237000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2117000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	5100000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4682000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	283000	USD
	us-gaap	Net Income Loss NetIncomeLoss	1463000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	317000	USD
	us-gaap	Net Income Loss NetIncomeLoss	1134000	USD
CY2016Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-288000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-596000	USD
CY2017Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-272000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-412000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2016Q4	us-gaap	Operating Expenses OperatingExpenses	40747000	USD
	us-gaap	Operating Expenses OperatingExpenses	84823000	USD
CY2017Q4	us-gaap	Operating Expenses OperatingExpenses	38038000	USD
	us-gaap	Operating Expenses OperatingExpenses	77028000	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	700000	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	2327000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	3725000	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9453000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10360000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1242000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1142000	USD
CY2016Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-189000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-98000	USD
CY2017Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	46000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	66000	USD
CY2016Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-189000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-98000	USD
CY2017Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	46000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	66000	USD
CY2017Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1927000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1966000	USD
CY2016Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-150000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-321000	USD
CY2017Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-169000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-147000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	200000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	250000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	237000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2117000	USD
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2017Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5266000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4052000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3127000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4644000	USD
CY2016Q4	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2017Q4	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1000000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1000000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	600000	USD
CY2016Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	300000	USD
CY2017Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	300000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	500000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-106992000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-106108000	USD
CY2016Q4	us-gaap	Sales Revenue Net SalesRevenueNet	48947000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	103841000	USD
CY2017Q4	us-gaap	Sales Revenue Net SalesRevenueNet	49482000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	98609000	USD
CY2016Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17207000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34987000	USD
CY2017Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14643000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30224000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1515000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1453000	USD
CY2017Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	5000000	USD
CY2017Q4	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	4800000	USD
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	45107	shares
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	250000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	14527000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	16505000	USD
CY2017Q2	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	215000	USD
CY2017Q4	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	407000	USD
CY2016Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14132000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14176000	shares
CY2017Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14153000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14117000	shares
CY2016Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13840000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13830000	shares
CY2017Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13956000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13959000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounting guidance for financial instruments requires disclosure of significant concentrations of credit risk regardless of the degree of such risk. Financial instruments with significant credit risk include cash and investments.</font></div></div>
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for contingent liabilities in accordance with Accounting Standards Codification ("ASC") Topic 450, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies</font><font style="font-family:inherit;font-size:10pt;">. This guidance requires management to assess potential contingent liabilities that may exist as of the date of the financial statements to determine the probability and amount of loss that may have occurred, which inherently involves an exercise of judgment. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. For loss contingencies considered remote, no accrual or disclosures are generally made. Management has assessed potential contingent liabilities as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, and based on the assessment, there are no probable loss contingencies requiring accrual or disclosures within its financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Legal Accruals</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to commitments and obligations in the ordinary course of business, from time to time, the Company is subject to various claims, pending and potential legal actions, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of its business. Management assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because evaluating legal claims and litigation results are inherently unpredictable and unfavorable results could occur, assessing contingencies is highly subjective and requires judgments about future events. When evaluating contingencies, management may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed or asserted against the Company may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of a potential liability. Management regularly reviews contingencies to determine the adequacy of financial statement accruals and related disclosures. The amount of ultimate loss may differ from these estimates. It is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of one or more of these contingencies. Whether any losses finally determined in any claim, action, investigation or proceeding could reasonably have a material effect on the Company's business, financial condition, results of operations or cash flows will depend on a number of variables, including: the timing and amount of such losses; the structure and type of any remedies; the significance of the impact any such losses, damages or remedies may have on the consolidated financial statements; and the unique facts and circumstances of the particular matter that may give rise to additional factors.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Class Action Lawsuit: </font><font style="font-family:inherit;font-size:10pt;">As previously reported, on September 15, 2016, a purported securities class action was filed in the United States District Court for the District of Utah, entitled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Zhang v. LifeVantage Corp.</font><font style="font-family:inherit;font-size:10pt;">, Case No. 2:16-cv-00965-BCW (D. Utah filed Sept. 15, 2016). In this action (later recaptioned as </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">In re LifeVantage Corp. Securities Litigation</font><font style="font-family:inherit;font-size:10pt;">), plaintiff alleged that the Company, its Chief Executive Officer and former Chief Financial Officer violated Sections 10(b) and/or 20(a) of the Securities Exchange Act of 1934, 15 U.S.C. §§ 78j(b), 78t(a), and Rule 10b-5, 17 C.F.R. § 240.10b-5, promulgated thereunder. On June 15, 2017, the Court granted defendants’ motion to dismiss the amended complaint, without prejudice, and permitted lead plaintiffs to file a motion for leave to file a second amended complaint. On September 18, 2017, the Court denied lead plaintiffs’ motion for leave to amend and entered final judgment in favor of LifeVantage and the other defendants and dismissed the case with prejudice. On October 17, 2017, the parties executed a stipulation whereby lead plaintiffs agreed not to take an appeal from the final judgment of dismissal in favor of defendants in exchange for mutual releases, without payment of any consideration by or on behalf of defendants. This case is now concluded.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative Action Lawsuits:</font><font style="font-family:inherit;font-size:10pt;"> Also, as previously reported, on October 11, 2016, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> purported shareholder derivative actions were filed in the Third District Court of the State of Utah, Salt Lake County, entitled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Johnson v. Jensen</font><font style="font-family:inherit;font-size:10pt;">, Case No. 160906320 MI (Utah Dist. filed Oct. 11, 2016), and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rupp v. Jensen</font><font style="font-family:inherit;font-size:10pt;">, Case No. 160906321 MI (Utah Dist. filed Oct. 11, 2016). In these actions (which are substantively identical), plaintiffs, purportedly on behalf of the Company, alleged that the Company’s Chief Executive Officer, former Chief Financial Officer and members of the board of directors breached their fiduciary duties owed to the Company in connection with the matters alleged in the securities class action lawsuit noted above. On October 19, 2016, the Court entered an order consolidating the two actions under the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Johnson</font><font style="font-family:inherit;font-size:10pt;"> case number, with the new caption </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">In re LifeVantage Corp. Derivative Litigation</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 30, 2017, another purported shareholder derivative action was filed in the United States District Court for the District of Utah, entitled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hansen v. Jensen</font><font style="font-family:inherit;font-size:10pt;">, Case No. 2:17 cv-00075-DN (D. Utah filed Jan. 30, 2017). In this action, plaintiff, purportedly on behalf of the Company, alleged that the Company’s Chief Executive Officer, former Chief Financial Officer and members of the board of directors violated Section 14(a) of the Securities Exchange Act of 1934, 15 U.S.C. § 78n(a), and breached their fiduciary duties owed to the Company in connection with the matters alleged in the securities class action lawsuit noted above. On February 27, 2017, another purported shareholder derivative action was filed in the United States District Court for the District of Utah, entitled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Baker v. Jensen</font><font style="font-family:inherit;font-size:10pt;">, Case No. 2:17-cv-00141-PMW (D. Utah filed Feb. 27, 2017). Also, on April 24, 2017, another purported shareholder derivative action was filed in the United States District Court for the District of Utah, entitled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inforzato v. Jensen</font><font style="font-family:inherit;font-size:10pt;">, Case No. 2:17-cv-00317-JNP (D. Utah filed Apr. 24, 2017). In these actions, plaintiffs, also purportedly on behalf of the Company, made similar allegations as the plaintiff in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hansen v. Jensen</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following and in light of the dismissal with prejudice of the securities class action lawsuit noted above, the Company requested that the plaintiffs in the shareholder derivative actions agree to dismiss their lawsuits voluntarily and without payment of any consideration by or on behalf of defendants or the Company. On October 31, 2017, the plaintiffs in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">In re LifeVantage Corp. Derivative Litigation</font><font style="font-family:inherit;font-size:10pt;"> stipulated to voluntary dismissal of their consolidated action without payment of any consideration by or on behalf of defendants or the Company. On November 17, 2017, the parties in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inforzato</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hansen</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Baker</font><font style="font-family:inherit;font-size:10pt;"> stipulated to voluntary dismissal of those actions without payment of any consideration by or on behalf of defendants or the Company.</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 20, 2017, the Courts in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">In re LifeVantage Corp. Derivative Litigation</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hansen</font><font style="font-family:inherit;font-size:10pt;"> granted the stipulated motions to dismiss, and on December 12, 2017, the Court in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Baker</font><font style="font-family:inherit;font-size:10pt;"> granted the stipulated motion to dismiss.On November 27, 2017, the Court in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inforzato</font><font style="font-family:inherit;font-size:10pt;"> ordered, pursuant to Rule 23.1(c) of the Federal Rules of Civil Procedure, that the parties give notice to shareholders of the voluntary dismissal without prejudice of the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inforzato</font><font style="font-family:inherit;font-size:10pt;"> action before the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inforzato</font><font style="font-family:inherit;font-size:10pt;"> action could be dismissed, which the Company provided on January 8, 2018.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Matters.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">In addition to the matters described above, the Company also may become involved in other litigation and regulatory matters incidental to its business and the matters disclosed in this quarterly report on Form 10-Q, including, but not limited to, product liability claims, regulatory actions, employment matters and commercial disputes. The Company intends to defend itself in any such matters and does not currently believe that the outcome of any such matters will have a material adverse effect on the Company's business, financial condition, results of operations and cash flows.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company prepares the condensed consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America (GAAP). In preparing these statements, the Company is required to use estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates and assumptions. On an ongoing basis, the Company reviews its estimates, including those related to inventory valuation and obsolescence, sales returns, income taxes and tax valuation reserves, share-based compensation, and loss contingencies.</font></div></div>

Files In Submission

Name	View Source	Status
0000849146-18-000041-index-headers.html	Edgar Link	pending
0000849146-18-000041-index.html	Edgar Link	pending
0000849146-18-000041.txt	Edgar Link	pending
0000849146-18-000041-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lfvn-20171231.xml	Edgar Link	completed
lfvn-20171231.xsd	Edgar Link	pending
lfvn-20171231_cal.xml	Edgar Link	unprocessable
lfvn-20171231_def.xml	Edgar Link	unprocessable
lfvn-20171231_lab.xml	Edgar Link	unprocessable
lfvn-20171231_pre.xml	Edgar Link	unprocessable
lfvn_123117x10q.htm	Edgar Link	pending
lfvn_123117xex311.htm	Edgar Link	pending
lfvn_123117xex312.htm	Edgar Link	pending
lfvn_123117xex321.htm	Edgar Link	pending
lfvn_123117xex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LFVN
Lifevantage Corp Stock $lfvn

2017 Q4 Form 10-Q Financial Statement

#000084914618000041 Filed on February 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LFVN Lifevantage Corp Stock $lfvn

2017 Q4 Form 10-Q Financial Statement

#000084914618000041 Filed on February 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LFVN
Lifevantage Corp Stock $lfvn